Hong Kong: Local Market Insights from MNC Heads
While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub…
Company information:
Hybribio is a leading provider for in vitro diagnostic assays in Greater China with fully integrated operation chain from R&D, manufacturing, sales & marketing to after-sales technical support service. As of year 2016, over 16 million tests of our HPV Genotyping test has been performed in China. Furthermore, we are the sole company collaborating with the Ministry of Health in Chinese Government to establish the first HPV database system in China. Based on technological platforms such as our proprietary flow-through hybridization technology, real-time PCR technology, and high throughput sequencing, our two major R&D lines – infectious pathogens detection and genetic disease detection – include human papillomavirus (HPV), thalassemia, G6PD, hearing loss susceptibility, phenylketonuria (PKU), and early cancer detection etc. Our products have been widely used in the fields of clinical detection, large scale screening, and prenatal and neonatal management.
Address: 27/F, Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong
Tel.: (+852) 2851 8029
Website: http://hybribio.com/
Email: marketing@hybribio.com
While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub…
Hong Kong provides some of the best and most efficient healthcare in Asia, with Hong Kongers living to over 85 on average (compared to 83 in Singapore and 78 in…
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It…
Insighta, formed this year as a 50/50 joint venture between genomics-focused outfit Prenetics and one of the city’s most feted scientific sons, Professor Dennis Lo, is aiming to change the…
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and…
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and…
One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and…
Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and…
Serial entrepreneur Danny Yeung highlights the work of his Hong Kong-based genomics-driven firm Prenetics in prevention, early detection and targeted therapy. Having recently announced a USD 200 million joint venture…
See our Cookie Privacy Policy Here
